Iovance Biotherapeutics(NASDAQ) IOVA

Iovance Biotherapeutics makes new treatments for people with cancer. These therapies use a person's own immune cells to fight tumors. The medicines help when other cancer treatments have stopped working.

What Does Iovance Sell?

• Amtagvi: One-time treatment for advanced melanoma that uses a patient's own immune cells to attack cancer.
• Proleukin: Biologic medicine used to support cell therapy treatments or to treat specific skin and kidney cancers.
• TIL Platform: Manufacturing technology that grows billions of cancer-fighting cells, known as tumor infiltrating lymphocytes, from a patient's tumor.

Recent Milestones and Acquisitions

• Acquired worldwide rights to Proleukin in May 2023 to secure a supply of a key treatment component.
• Received marketing authorization in Australia for its primary melanoma treatment in June 2026.
• Ended a contract with an outside manufacturer in early 2026 to move all production in-house.
• Resubmitted a marketing application for its lead therapy to regulators in the United Kingdom in July 2026.

A Specialized Manufacturing Network

Iovance operates a dedicated cell therapy center in Philadelphia that can treat more than 5,000 patients annually. This facility handles the complex logistics of shipping individualized immune cells to treatment centers in North America, Europe, and Asia Pacific.

Key Financial Statistics

• Total product revenue reached $99.3 million for the three-month period ended June 30, 2026, up 66% year over year.
• Net loss was $47.3 million for the three-month period ended June 30, 2026, down 58% year over year.
• Research and development expenses were $58.9 million for the three-month period ended June 30, 2026, a 24% decrease from 2025.
• Cash, equivalents, and short-term investments totaled $303.7 million as of June 30, 2026.

Bottom Line

Iovance has transitioned from a clinical-stage research firm to a commercial company with approved cancer therapies. Its focus on internal manufacturing and international expansion supports its goal of delivering personalized medicine to a wider patient base.